# Pembrolizumab combined with surgical treatment for spontaneously ruptured undifferentiated pleomorphic sarcoma of the liver: a case report and literature review

## TL;DR

This case report describes successful treatment of a rare liver cancer using surgery and pembrolizumab, suggesting a promising approach for this aggressive disease.

## Contribution

The paper presents a novel case of combining pembrolizumab with surgery for undifferentiated pleomorphic sarcoma of the liver.

## Key findings

- An 83-year-old male with UPSL showed favorable clinical outcomes after surgery and pembrolizumab treatment.
- Combining immunotherapy with surgery may improve prognosis for this rare and aggressive liver cancer.
- No standardized treatment exists for UPSL, but this case highlights a potential new therapeutic strategy.

## Abstract

Undifferentiated pleomorphic sarcoma of the liver (UPSL) is a rare pathological type characterized by an undefined mechanism, low incidence, high metastatic rate, aggressive behavior, and an inferior prognosis; no standardized treatment protocols or guidelines currently exist. This article reports the case of an 83-year-old male with UPSL confirmed through surgical resection and pathological biopsy. Postoperatively, he received eight cycles of pembrolizumab, which resulted in a favorable clinical efficacy. With advances in medical technology, the integration of surgery and immunotherapy is expected to play an essential role in treating this rare disease and monitoring its prognosis.